Vaccine

New strategic partnership to develop next-generation T cell detection reagents

Thursday, July 2, 2020 - 2:00pm

SHANGHAI, China and COPENHAGEN, Denmark, July 2, 2020 /PRNewswire/ --Today two MedTech companies, Polaris Biology of China and Tetramer Shop of Denmark, announce a strategic partnership to co-develop and distribute technologies that accelerate T cell science.

Key Points: 
  • SHANGHAI, China and COPENHAGEN, Denmark, July 2, 2020 /PRNewswire/ --Today two MedTech companies, Polaris Biology of China and Tetramer Shop of Denmark, announce a strategic partnership to co-develop and distribute technologies that accelerate T cell science.
  • With quick, easy access to metal-labelled tetramers, researchers will be able to detect hundreds of T cell specificities in a single sample, accelerating therapeutic development.
  • This technology holds the potential to develop a new generation of MHC tetramers for the analysis of T cell immune monitoring.
  • Tetramer Shop serves a range of global customers from academic research institutions to therapeutic development labs including cancer vaccine and T cell therapy development.

Novavax Announces Updates to Leadership Team

Thursday, July 2, 2020 - 1:30pm

Novavax also announced the promotion of Brian Webb to Senior Vice President, Manufacturing, with responsibility for overseeing antigen manufacturing and supply activities in support of Novavax vaccine candidates.

Key Points: 
  • Novavax also announced the promotion of Brian Webb to Senior Vice President, Manufacturing, with responsibility for overseeing antigen manufacturing and supply activities in support of Novavax vaccine candidates.
  • Franks extensive commercial and sales expertise will be invaluable to Novavax transformation into a commercial stage organization, said Stanley C. Erck, President and Chief Executive Officer of Novavax.
  • Mr. Czworka brings more than two decades of biopharmaceutical experience to Novavax, most recently serving as Vice President, Global Customer Engagement at U.S. Pharmacopeia.
  • Both vaccine candidates incorporate Novavax proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.

COVID-19 Newsletter: Vaccine Developments, Therapeutics Experiments and Diagnostics/Devices Advances - ResearchAndMarkets.com

Thursday, July 2, 2020 - 10:01am

The "COVID-19 - Vaccine Development, Therapeutics Experiments and Diagnostics/Devices Advances - Bundle" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 - Vaccine Development, Therapeutics Experiments and Diagnostics/Devices Advances - Bundle" newsletter has been added to ResearchAndMarkets.com's offering.
  • The newsletter includes the following:
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200702005163/en/

Canadians want COVID-19 vaccine, progress slow

Thursday, July 2, 2020 - 9:45am

According to Meladul Haq Ahmadzai, CEO of Taleam Systems and a Global Health researcher explains that everyone wants a vaccine cure in Canada, but the progress is slow.

Key Points: 
  • According to Meladul Haq Ahmadzai, CEO of Taleam Systems and a Global Health researcher explains that everyone wants a vaccine cure in Canada, but the progress is slow.
  • Ahmadzai says, Some scientists have said that a vaccine would be available at the end of the year, but others predict a vaccine would be created much faster.
  • During COVID-19 pandemic, health institutions in Canada werent prepared to respond to the Coronavirus due to limited health stock quantity.
  • Canada lost 2 million jobs in April 2020 , were mostly or all eliminated because of the effects of the virus.

Sorrento Announces Selection of T-VIVA-19™ as Targeted Protein Vaccine Candidate for SARS-CoV-2

Wednesday, July 1, 2020 - 5:06pm

T-VIVA-19 (targeted virus vaccine against COVID-19) is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc.

Key Points: 
  • T-VIVA-19 (targeted virus vaccine against COVID-19) is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc.
  • Novel protein to progress as priority vaccine candidate development program.
  • T-VIVA-19 is a recombinant fusion protein of the spike protein S1-domain and the Fc portion of the human IgG1 antibody (rS1-Fc).
  • Immunization with the rS1-Fc protein via intramuscular and intravenous injections induced antibodies against the SARS-CoV-2 protein in all mice within the first week of administration.

BioNTech to Hold Webcast to Present Early Positive Data from Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2

Wednesday, July 1, 2020 - 2:28pm

A replay of the webcast will be available shortly after the conclusion of the call and archived on the Companys website for 30 days following the call.

Key Points: 
  • A replay of the webcast will be available shortly after the conclusion of the call and archived on the Companys website for 30 days following the call.
  • Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
  • The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.
  • Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.

Bavarian Nordic Announces European Marketing Authorization for Ebola Vaccine

Wednesday, July 1, 2020 - 2:23pm

COPENHAGEN, Denmark, July 1, 2020 Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced todaythat the European Commission has granted marketing authorization for MVABEA (MVA-BN Filo) together with ZABDENO (Ad26.ZEBOV), which collectively constitute Janssens Ebola vaccine regimen.

Key Points: 
  • COPENHAGEN, Denmark, July 1, 2020 Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced todaythat the European Commission has granted marketing authorization for MVABEA (MVA-BN Filo) together with ZABDENO (Ad26.ZEBOV), which collectively constitute Janssens Ebola vaccine regimen.
  • The marketing authorization has been granted to Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson who obtained a worldwide license to develop, manufacture and commercialize MVA-BN Filo from Bavarian Nordic in 2014.
  • The Ebola vaccine regimen is specifically designed to induce long-term immunity against the Ebola virus, in adults and children aged one year and above.
  • We are proud to have supported the development of a new Ebola vaccine, which represents the second European approval of a product based on our MVA-BN platform technology, said Paul Chaplin, President & CEO of Bavarian Nordic.

Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine

Wednesday, July 1, 2020 - 2:22pm

Johnson & Johnson today announced that the European Commission (EC) has granted Marketing Authorisation for its Janssen Pharmaceutical Companies Ebola vaccine regimen for the prevention of Ebola Virus Disease.

Key Points: 
  • Johnson & Johnson today announced that the European Commission (EC) has granted Marketing Authorisation for its Janssen Pharmaceutical Companies Ebola vaccine regimen for the prevention of Ebola Virus Disease.
  • The European approval of Janssens Ebola vaccine regimen is a landmark moment both for our Company and in the worlds battle against the deadly Ebola virus.
  • Janssens Ebola vaccine regimen is specifically designed to induce long-term immunity against the Ebola virus3,4 in adults and children aged one year and above.
  • Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssens Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC).

Combating The Coronavirus With Pure Water

Wednesday, July 1, 2020 - 1:40pm

For over 90 years, MECO has provided innovative water purification systems to leading industries around the world.

Key Points: 
  • For over 90 years, MECO has provided innovative water purification systems to leading industries around the world.
  • MECO water is used by pharmaceutical and biotechnology companies for the manufacturing of medical devices, diagnostics, vaccines, generic medicines, and nutritional products.
  • Today, leading biopharmaceutical companies use these types of water purification systems to produce massive volumes of Purified Water (PW), Water for Injection (WFI) and Pure Steam to develop medication, manufacture IV fluid, final rinsing and sterilization of product packaging, produce COVID-19 tests, and continual development on a coronavirus vaccine.
  • MECO is a world leader in the design and construction of engineered products for water purification serving industries where water is considered a critical utility.

Analysis of the Emerging Disease Landscape: Novel Coronavirus (COVID-19) - May 2020 - ResearchAndMarkets.com

Wednesday, July 1, 2020 - 1:20pm

The "Analysis of the Emerging Disease Landscape - COVID-19 - May 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Analysis of the Emerging Disease Landscape - COVID-19 - May 2020" report has been added to ResearchAndMarkets.com's offering.
  • The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space.
  • The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions.
  • A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring.